AR018169A1 - Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret - Google Patents
Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiretInfo
- Publication number
- AR018169A1 AR018169A1 ARP990101363A ARP990101363A AR018169A1 AR 018169 A1 AR018169 A1 AR 018169A1 AR P990101363 A ARP990101363 A AR P990101363A AR P990101363 A ARP990101363 A AR P990101363A AR 018169 A1 AR018169 A1 AR 018169A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- alkyl
- compounds
- optionally substituted
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere al uso de los compuestos derivado trisustituido de 1,3,5-triazina de la formula (I), los N-oxidos, las sales de adicion farmacéuticamenteaceptables y las formas estereoquímicamente isoméricas de los mismos, en los cuales A es CH, CR4 o N;n es 0, 1, 2, 3 o 4; cada uno de R1 y R2 esindependientemente seleccionado entre hidrogeno, hidroxi, alquilo C1-12, alquiloxi C1-12, alquilcarbonilo C1-12, alquiloxicarbonilo C1-12, arilo, amino,mono- o di(alquil C1-12)amino, mono- o di(alquil C1-12)aminocarbonilo donde cada uno de los grupos alquilo C1-12 mencionados puede ser sustituido optativa eindividualmente o R1 y R2 juntos pueden formar pirrolidinilo, piperidinilo, morfolinilo, azido o mono- o di(alquil C1-12)aminoalquilideno C1-4; R3 eshidrogeno, arilo, alquilcarbonilo C1-6, alquilo C1-6 optativamente sustituido y cada R4 es independientemente hidroxi, halo, alquilo C1-6, alquiloxi C1-6,ciano, aminocarbonilo, nitro, amino, trihalometilo o trihalometiloxi; L es -X-R5 o -X-Alc-R6, donde cada uno de R5 y R6 es independientemente indanilo,indolilo o fenilo; cada uno de dichos indanilo, indolilo o fenilo puede estar sustituido y X es -NR3, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- o S(=O)2-; ariloes fenilo optativamente sustituido; Het esun radical heterocíclico alifático o aromático optativamente sustituido; para la elaboracion de unmedicamento para el tratamiento de sujetos que sufren la infeccion por HIV (Virus de Inmunodeficiencia Humana). Además se relaciona con nuevos compuestosque constituyen un subgrupo de los compuestos de la formula (I), con su proceso de preparacion y con composiciones farmacéuticas que los contienen,un proceso para su preparacion, la combinacion de dichos compuestos con otro compuesto antiretroviraly un producto que los contiene, compuestosintermediarios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7963398P | 1998-03-27 | 1998-03-27 | |
EP98201589A EP0945447A1 (en) | 1998-03-27 | 1998-05-14 | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AR018169A1 true AR018169A1 (es) | 2001-10-31 |
Family
ID=22151790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101363A AR018169A1 (es) | 1998-03-27 | 1999-03-26 | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret |
Country Status (33)
Country | Link |
---|---|
US (3) | US6150360A (es) |
EP (2) | EP0945447A1 (es) |
JP (1) | JP2002511390A (es) |
KR (1) | KR100593396B1 (es) |
CN (1) | CN1157386C (es) |
AP (1) | AP1475A (es) |
AR (1) | AR018169A1 (es) |
AT (1) | ATE295355T1 (es) |
AU (1) | AU758624C (es) |
BG (1) | BG64903B1 (es) |
BR (1) | BR9909197A (es) |
CA (1) | CA2324921C (es) |
DE (1) | DE69925256T2 (es) |
DK (1) | DK1066269T3 (es) |
EA (1) | EA004540B1 (es) |
EE (1) | EE200000535A (es) |
ES (1) | ES2243056T3 (es) |
HK (1) | HK1032394A1 (es) |
HR (1) | HRP20000621A2 (es) |
HU (1) | HUP0101372A3 (es) |
ID (1) | ID26043A (es) |
IL (1) | IL138670A (es) |
NO (1) | NO317425B1 (es) |
NZ (1) | NZ506787A (es) |
OA (1) | OA11493A (es) |
PL (1) | PL194660B1 (es) |
PT (1) | PT1066269E (es) |
SI (1) | SI1066269T1 (es) |
SK (1) | SK14052000A3 (es) |
TR (1) | TR200002761T2 (es) |
TW (1) | TW570917B (es) |
WO (1) | WO1999050256A1 (es) |
ZA (1) | ZA200006042B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005423B1 (ru) * | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
US6645964B1 (en) * | 1999-11-29 | 2003-11-11 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agent |
US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
ES2542326T3 (es) | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
DK1282607T3 (en) | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US6887873B2 (en) * | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7132423B2 (en) * | 2001-09-21 | 2006-11-07 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7169785B2 (en) * | 2001-09-21 | 2007-01-30 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
IL160984A0 (en) * | 2001-09-21 | 2004-08-31 | Reddy Us Therapeutics Inc | Triazine derivatives and pharmaceutical compositions containing the same |
US7163943B2 (en) * | 2001-09-21 | 2007-01-16 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7112587B2 (en) * | 2001-09-21 | 2006-09-26 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
EP1441683A4 (en) * | 2001-10-12 | 2005-10-26 | Univ New York | TRISUBSTITUTED TRIAZINE COMPOUNDS WITH ANTI-TUBULIN ACTIVITY, METHODS OF MAKING AND USING SAME |
WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
KR100875362B1 (ko) | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
US7419984B2 (en) * | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
MXPA05008368A (es) * | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. |
US20070232572A1 (en) * | 2003-02-07 | 2007-10-04 | Aventis Pharma S.A. | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
WO2005011702A1 (en) | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
AU2004259346A1 (en) * | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
RU2401833C2 (ru) * | 2004-08-10 | 2010-10-20 | Янссен Фармацевтика Н.В. | Производные 1, 2, 4-триазин-6-она, ингибирующие вич |
CN101027288B (zh) | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
BRPI0515935B8 (pt) | 2004-09-30 | 2021-05-25 | Janssen Sciences Ireland Uc | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica |
TW200626574A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
BRPI0517272A (pt) | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | derivados de pirimidina bicìclicos de inibição de hiv |
US7592451B2 (en) * | 2005-06-23 | 2009-09-22 | New York University | Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments |
WO2007071199A1 (fr) * | 2005-12-22 | 2007-06-28 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
CA2674178C (en) | 2006-12-29 | 2015-11-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 6-substituted pyrimidines |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
AU2011320024B2 (en) | 2010-10-27 | 2014-10-30 | The Walter And Eliza Hall Institute Of Medical Research | Novel anti-cancer agents |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
US9914709B2 (en) * | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
EP3122736A1 (en) * | 2014-03-28 | 2017-02-01 | Basf Se | Diaminotriazine derivatives as herbicides |
PT3394040T (pt) | 2015-12-24 | 2022-03-24 | Univ California | Reguladores de cftr e seus métodos de uso |
AU2018321926B2 (en) | 2017-08-24 | 2023-09-21 | The Regents Of The University Of California | Ocular pharmaceutical compositions |
CN109053613A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2742466A (en) * | 1956-04-17 | Chx n nhx c c | ||
US2671810A (en) * | 1952-05-24 | 1954-03-09 | Du Pont | Long-chain diketones |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US4096206A (en) | 1976-02-09 | 1978-06-20 | Borg-Warner Corporation | Flame-retardant triazines |
US4652645A (en) * | 1983-11-16 | 1987-03-24 | Ciba-Geigy Corporation | Cationic compounds |
EP0541966A3 (en) * | 1991-11-15 | 1994-09-07 | American Cyanamid Co | Process for preparing amide derivatives from halomines and acid halides |
US5283274A (en) * | 1992-06-19 | 1994-02-01 | Uniroyal Chemical Company, Inc. | Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters |
BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
GB9519197D0 (en) * | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
CN1163401A (zh) * | 1996-02-13 | 1997-10-29 | 李占元 | 全自动血球计数仪试剂及配制方法 |
WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
-
1998
- 1998-05-14 EP EP98201589A patent/EP0945447A1/en not_active Withdrawn
-
1999
- 1999-03-24 SK SK1405-2000A patent/SK14052000A3/sk unknown
- 1999-03-24 CA CA002324921A patent/CA2324921C/en not_active Expired - Fee Related
- 1999-03-24 AT AT99917863T patent/ATE295355T1/de not_active IP Right Cessation
- 1999-03-24 EP EP99917863A patent/EP1066269B1/en not_active Expired - Lifetime
- 1999-03-24 ID IDW20001895A patent/ID26043A/id unknown
- 1999-03-24 CN CNB998044474A patent/CN1157386C/zh not_active Expired - Fee Related
- 1999-03-24 DE DE69925256T patent/DE69925256T2/de not_active Expired - Fee Related
- 1999-03-24 EA EA200000993A patent/EA004540B1/ru not_active IP Right Cessation
- 1999-03-24 PL PL99343195A patent/PL194660B1/pl not_active IP Right Cessation
- 1999-03-24 WO PCT/EP1999/002044 patent/WO1999050256A1/en not_active Application Discontinuation
- 1999-03-24 KR KR1020007007971A patent/KR100593396B1/ko not_active IP Right Cessation
- 1999-03-24 DK DK99917863T patent/DK1066269T3/da active
- 1999-03-24 HU HU0101372A patent/HUP0101372A3/hu unknown
- 1999-03-24 ES ES99917863T patent/ES2243056T3/es not_active Expired - Lifetime
- 1999-03-24 BR BR9909197-6A patent/BR9909197A/pt not_active Application Discontinuation
- 1999-03-24 SI SI9930807T patent/SI1066269T1/xx unknown
- 1999-03-24 TR TR2000/02761T patent/TR200002761T2/xx unknown
- 1999-03-24 AP APAP/P/2000/001913A patent/AP1475A/en active
- 1999-03-24 JP JP2000541160A patent/JP2002511390A/ja active Pending
- 1999-03-24 AU AU35997/99A patent/AU758624C/en not_active Ceased
- 1999-03-24 NZ NZ506787A patent/NZ506787A/xx unknown
- 1999-03-24 EE EEP200000535A patent/EE200000535A/xx unknown
- 1999-03-24 PT PT99917863T patent/PT1066269E/pt unknown
- 1999-03-25 US US09/276,362 patent/US6150360A/en not_active Expired - Fee Related
- 1999-03-26 TW TW088104756A patent/TW570917B/zh not_active IP Right Cessation
- 1999-03-26 AR ARP990101363A patent/AR018169A1/es unknown
-
2000
- 2000-08-08 US US09/634,340 patent/US6372729B1/en not_active Expired - Fee Related
- 2000-08-28 BG BG104716A patent/BG64903B1/bg unknown
- 2000-09-19 HR HR20000621A patent/HRP20000621A2/hr not_active Application Discontinuation
- 2000-09-25 IL IL13867000A patent/IL138670A/xx not_active IP Right Cessation
- 2000-09-26 NO NO20004809A patent/NO317425B1/no unknown
- 2000-09-27 OA OA1200000266A patent/OA11493A/en unknown
- 2000-10-26 ZA ZA200006042A patent/ZA200006042B/xx unknown
-
2001
- 2001-04-20 HK HK01102801A patent/HK1032394A1/xx not_active IP Right Cessation
-
2002
- 2002-02-05 US US10/067,383 patent/US6774235B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
AR014785A1 (es) | Derivados de pirimidina, uso de dichos derivados para la preparacion de medicamentos para el tratamiento de hiv,composicion farmaceutica que los comprende,procedimiento para prepararla, procedimiento para preparar dichos derivados, e intermediarios utiles en la preparacion de dichos derivados. | |
EA200000990A1 (ru) | Вич-ингибирующие производные пиримидина | |
AR008864A1 (es) | DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
DK0620216T3 (da) | Benzamidderivater og deres anvendelse som vasopressinantagonister | |
EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
AR034448A1 (es) | Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
AR017182A1 (es) | Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. | |
ES2123039T3 (es) | Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
ES2118203T3 (es) | Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
AR008875A1 (es) | Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos. | |
AR016480A1 (es) | Azoles hidrosolubles como antifungicos de amplio espectro, un proceso para su preparacion, un intermediario y una composicion farmaceutica que los comprende y el uso d elos mismos en la elaboracion de un medicamento | |
NO930143D0 (no) | Piperidinforbindelser, deres fremstilling og bruk | |
AR003412A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquenil)-2h-imidazol-2-ona, procedimiento para su preparacion, composicion que los comprenden, procedimiento para obtenerdicha composicion y uso de dichos compuestos para preparar medicamentos. | |
AR013360A1 (es) | Derivados de 6-azauracilo inhibidores de il-5, procedimiento para su preparacion, composicion que los contiene, procedimiento para preparardicha composicion, uso de dicho compuesto para la manufactura de medicamentos, de composiciones y procedimiento de marcado de un receptor. | |
AR029618A1 (es) | Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos | |
NO950136L (no) | 4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamider | |
DE68921719T2 (de) | Amphotericin B Derivate. | |
ATE500231T1 (de) | Hiv hemmende pyrimidin derivate | |
ES2159526T3 (es) | Nuevos derivados de 4-(3-benzofuranil)piperidinilo y 4-(3-benzotienil)piperidinilo y composiciones farmaceuticas que los contienen. | |
AR002264A1 (es) | 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |